Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
Policy & Regulation India Launches

Manufacturing Part Of GSK Proposal For Single Dose Antimalarial In India

  • Analysis

Executive Summary

GlaxoSmithKline has proposed to market and manufacture antimalarial Krintafel in India and an expert panel has sought additional information to progress a review of these plans. GSK and partner MMV aim to ensure that the cost of the therapy does not impede access.

You may also be interested in...



Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit

The latest drug development news and highlights from our US FDA Performance Tracker.

GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing

Approval could bring GlaxoSmithKline a tropical disease priority review voucher.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Table

View full table

Topics

Related Companies

Tags:
Policy & Regulation India Launches
UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By